Stock Ratings / Health Care / SION / dividends

UPB (42) ADAG (30) ANTX (46) ORMP (41) ⌘ Pro Terminal →

Sionna Therapeutics Inc. (SION) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Where is SION trading relative to its 50-day, 200-day, and 52-week technical levels?

SION last traded at $3.87 (-3.25% on volume of 534,393 shares), positioning the stock -28.47% below its 50-day simple moving average ($5.41) and -87.07% below its 200-day simple moving average ($29.93). Across its 52-week range of $3.55 to $54.97, SION sits at the 0.6% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.39 to $4.35).

Q: Does SION pay a dividend and is it safe?

Sionna Therapeutics Inc. (SION) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$3.87 -3.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.84

Sionna Therapeutics Inc. (SION) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $180.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SION Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SION stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Sionna Therapeutics Inc. (NASDAQ: SION) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $3.87 (-3.25% 1D, market cap $180.8M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SION ranks #580 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SION compare to UPB and ADAG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SION carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.3%. By comparison, UPB (Upstream Bio Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $179.1M) and ADAG (Adagene Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.0M). Among the 5-stock peer group, SION leads on earnings multiple (N/A) while ORMP leads on capital efficiency (-7.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SION?

▼

Per SION's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002036042), Sionna Therapeutics Inc. generated $0 in revenue, -$75.3M in net income, and -$66.7M in free cash flow against $326.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.84 (-0.77%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SION)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY SION SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 29.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.69-14.5% Next Q

Q2 (-2Q)

Grade D$4.01-8% Next Q

Q3 (-1Q)

Grade D$3.69+4.9% Next Q

Current

Grade D-$3.87-7.8% Hist 90D α

Trajectory: D (46) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SION Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SION currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.41) and Max Pain ($4.06) forces dealer call-delta covering toward $57.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SION• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SION Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SION)

✓Walkthrough of SION's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SION // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -90.43%🛡️ HOLDING TREND SUPPORT

2026-11-02O $3.90H $3.93L $3.68C $3.87VOL 131.2K

RES: $61.39SUP: $3.32SMA50: $5.41SMA200: $29.93

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SION Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SION Butterfly Map → + Track SION →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SION today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SION. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SION today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SION)

Health Care Rank #580 of 1016 ⚔️ UPB vs SION Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SION vs. UPB, ADAG, ANTX, ORMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sionna Therapeutics Inc. (SION) ranks #580 by composite RQD confidence (38/100, grade D-) and #589 by equity capitalization ($180.8M). Within this direct 5-issuer industry benchmark cohort, SION leads on earnings valuation at N/A trailing P/E, while ORMP leads on capital efficiency and profitability with -7.8% ROIC and 0.7% gross margin. ANTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SION at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SION ACTIVE Sionna Therapeutics Inc.	D-	38/100	—	—	-28.3%	-3.25%	$180.8M	Benchmark Subject
UPB Upstream Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$179.1M	/upb-vs-sion →
ADAG Adagene Inc.	E	30/100	—	—	-35.0%	-6.34%	$177.0M	/adag-vs-sion →
ANTX AN2 Therapeutics Inc.	D	46/100	—	—	-35.0%	-3.41%	$177.0M	/antx-vs-sion →
ORMP Oramed Pharmaceuticals Inc.	D-	41/100	—	0.7%	-7.8%	-2.84%	$176.0M	/ormp-vs-sion →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002036042

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sionna Therapeutics Inc. (SION) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$75.3M, operating cash flow of -$66.3M, and free cash flow of -$66.7M (-26.2% YoY). On the balance sheet, SION closed FY2025 with $326.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$75.3M	-$66.3M	-$66.7M	$326.0M	—
FY2024 (FY)	2024-12-31	$0	-$61.7M	-$52.8M	-$52.8M	$185.8M	—

3. SION Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SION stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SION compare to UPB and ADAG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SION?

Where is SION trading relative to its 50-day, 200-day, and 52-week technical levels?

SION last traded at $3.87 (-3.25% on volume of 534,393 shares), positioning the stock -28.47% below its 50-day simple moving average ($5.41) and -87.07% below its 200-day simple moving average ($29.93). Across its 52-week range of $3.55 to $54.97, SION sits at the 0.6% percentile with a 14-day RSI of 29.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.39 to $4.35).

SION Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SION pay a dividend and is it safe?

Sionna Therapeutics Inc. (SION) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SION RQD Cockpit SION 12M Forecast SION Earnings & Move SION Dividends & DRIP SION Insiders & 13F SION Whale Options SION Profit Sankey SION News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SION — Sionna Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:41:50Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SION scores 38 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 7/20 (ROIC -28.3%; FCF yield 0%), indicating the company is not generating cash from operations and is consuming capital. Whale 13F Flow scores 6/20 (institutional accumulation and options positioning), a weak reading on institutional conviction. Insider Conviction scores 5/20 (SEC Form 4 and Congressional PTR cluster flow), the lowest pillar, signaling limited insider-side confidence in the data provided. Macro Regime Fit scores 10/20 (Beta 1.0; sector sensitivity), a middling reading. Forensic Balance Sheet scores 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), a mixed picture: leverage appears moderate, but the Piotroski reading is weak.

Taken together, the pillars describe an issuer with no reported revenue, sustained operating losses, and negative free cash flow, offset partly by a balance sheet that the source data does not show as acutely stressed. Potential upside drivers, as framed by the news wire, center on pipeline and conference-related developments; these are event-dependent and are not quantified in the source data. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data, and the RQD score reflects the absence of cash generation. Investors weighing this profile should note that the rating is a rules-based score derived from the supplied inputs, not a forecast of price direction.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-89.0M	$-75.3M	N/A	$-66.7M	$58.5M	N/A
FY 2024	$0.0M	$-70.6M	$-61.7M	N/A	$-52.8M	$37.8M	N/A

Per the SEC financials, reported revenue is $0.0M in both periods, and operating losses widened from $-70.6M to $-89.0M. Per market data, gross, operating, and net margins are each 0%, and ROIC is -28.3%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the forensic balance sheet pillar of the RQD rating. Reported cash rose from $37.8M to $58.5M, and Debt/Equity is 0.5, while the period-level Debt field is N/A in the source data.

Recent Catalysts & News Wire Analysis

Per the recent news feed (six items, all tagged to SION):

Price action: A Yahoo Finance headline reports the stock lost 37.6% over four weeks and raises the possibility of a trend reversal. Source data reports a -0.99% change on the latest print.
Pipeline: A Clinical Trial Vanguard item reports an advancement of a SION-451/SION-2222 combination based on SION-719 analysis.
Conferences: Items report a planned presentation of data at the 2026 North American Cystic Fibrosis Conference and participation in upcoming November 2026 investor conferences.
Insider activity: An Investing.com item references a Form 4 filing by Michael Cloonan (Director, President & CEO) for a transaction dated 17 September.
Seasonality: A Yahoo Finance Australia item references a seasonal returns chart.

All news items carry a YELLOW light and a MARKET WIRE impact label. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Open Questions

What is the composition of the SION-451/SION-2222 combination program, and what clinical milestones are scheduled?
What is the cash runway implied by the $58.5M reported cash against the $-66.7M FY 2025 FCF?
What drove the Form 4 transaction referenced for Michael Cloonan, and what was its size and direction?
Why are period-level debt and EPS reported as N/A, and what is the actual debt structure behind the Debt/Equity of 0.5?
What are the sources and timing of the stated 37.6% four-week decline, and how do they relate to the recent news flow?

SION Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sionna Therapeutics Inc. (SION) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SION Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 6h ago

Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Clinical Trial Vanguard • 9h ago

Sionna Advances SION-451/SION-2222 Combo Based on SION-719 Analysis

The Clinical Trial Vanguard report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 12h ago

Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com South Africa • 15h ago

Form 4 Sionna Therapeutics Inc: Michael Cloonan (Director, President & CEO) For: 17 September By Investing.com

Investing.com South Africa report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 18h ago

Sionna Therapeutics to Participate in Upcoming November 2026 Investor Conferences

Yahoo Finance report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance Australia • 21h ago

Sionna Therapeutics, Inc. (SION) Seasonal returns chart

Yahoo Finance Australia report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

SION Q2 2026 Earnings: Narrower-Than-Expected Loss Keeps Clinical-Stage Story on Track - Operating Margin Analysis

https://www.dars.gov.et/ report covering Sionna Therapeutics Inc. (SION) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SION Bull vs. Bear Conversation Board — What's Your Call at $3.87?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SION 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $3.52 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SION (D- • RQD 38/100) a Buy at $4.00?

Welcome to the SION (Sionna Therapeutics Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.08 (-23.0%)

Spot @ $4.00

Pump the brakes on SION — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SION, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Sionna Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.84 (+21.0%)

Spot @ $4.00

SION cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SION, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.00 (52-wk range $3.69 - $4.57), any beat on forward guidance forces shorts and underweight funds to chase.